Growing Psychedelic Interest Will Help Push Compass Pathways Stock Up 3X By 2022InvestorPlace • 08/04/21
COMPASS Pathways plc to announce second quarter 2021 financial results on 11 August 2021GlobeNewsWire • 08/04/21
COMPASS Pathways to Participate in BTIG and Canaccord Genuity Investor ConferencesGlobeNewsWire • 08/03/21
Danielle Schlosser joins COMPASS Pathways from Verily Life Sciences to lead clinical innovation and therapist trainingGlobeNewsWire • 07/21/21
COMPASS Pathways to participate in Cowen's Psychedelics & Novel Mechanisms in Neuropsychiatry Virtual SummitGlobeNewsWire • 07/07/21
COMPASS Pathways joins forces with King's College London and South London and Maudsley NHS Foundation Trust to accelerate psychedelic research and develop new models of mental health care in the UKGlobeNewsWire • 07/05/21
COMPASS Pathways launches new podcast “Everyone has a story: talking about mental health”GlobeNewsWire • 06/30/21
Compass Pathways Completes Target Administration Of Psilocybin Therapy In World's Largest StudyBenzinga • 06/29/21
COMPASS Pathways completes COMP360 psilocybin therapy administration for 216 patients in large-scale phase IIb psilocybin therapy trial for treatment-resistant depressionGlobeNewsWire • 06/28/21
COMPASS Pathways and Kings College London publish cognition results from COMP360 psilocybin study in healthy volunteersGlobeNewsWire • 06/03/21
COMPASS Pathways plc announces financial results and business highlights for the first quarter 2021GlobeNewsWire • 05/13/21
COMPASS Pathways plc to announce first quarter 2021 financial results on 13 May 2021GlobeNewsWire • 05/06/21
5 Top Medical Services Stocks to Beat COVID-Led Industry ChallengesZacks Investment Research • 04/28/21